A report from the Government Accountability Office says that seniors using specialty-tier drugs reached catastrophic Medicare coverage 55% of the time and the drugs accounted for most of seniors' out-of-pocket drug costs. The findings underscore the need for more generic competition in traditional as well as biotech treatments to provide patients with more options and give companies an incentive to cut prices, according to PCMA.

Related Summaries